DE69939593D1 - Polypeptide zur modulierung des überlebens von zellen - Google Patents

Polypeptide zur modulierung des überlebens von zellen

Info

Publication number
DE69939593D1
DE69939593D1 DE69939593T DE69939593T DE69939593D1 DE 69939593 D1 DE69939593 D1 DE 69939593D1 DE 69939593 T DE69939593 T DE 69939593T DE 69939593 T DE69939593 T DE 69939593T DE 69939593 D1 DE69939593 D1 DE 69939593D1
Authority
DE
Germany
Prior art keywords
death
p75ntr
present
survival
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939593T
Other languages
English (en)
Inventor
Perry Francis Bartlett
Elizabeth Jane Coulson
Katrina Fieldew
Manuel Baca
Trevor Kilpatrick
Cheema Surindar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP6353A external-priority patent/AUPP635398A0/en
Priority claimed from AUPP6351A external-priority patent/AUPP635198A0/en
Priority claimed from AUPQ0701A external-priority patent/AUPQ070199A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Application granted granted Critical
Publication of DE69939593D1 publication Critical patent/DE69939593D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69939593T 1998-10-06 1999-10-05 Polypeptide zur modulierung des überlebens von zellen Expired - Lifetime DE69939593D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPP6353A AUPP635398A0 (en) 1998-10-06 1998-10-06 A method of modulating cell survival and reagents useful for same
AUPP6351A AUPP635198A0 (en) 1998-10-07 1998-10-07 A method of modulating cell survival and reagents useful for same-ii
AUPQ0701A AUPQ070199A0 (en) 1999-06-01 1999-06-01 A method of modulating cell survival and reagents useful for same-iii
PCT/AU1999/000860 WO2000020578A1 (en) 1998-10-06 1999-10-05 A method of modulating cell survival and reagents useful for same

Publications (1)

Publication Number Publication Date
DE69939593D1 true DE69939593D1 (de) 2008-10-30

Family

ID=27158107

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939593T Expired - Lifetime DE69939593D1 (de) 1998-10-06 1999-10-05 Polypeptide zur modulierung des überlebens von zellen

Country Status (6)

Country Link
US (3) US20020137188A1 (de)
EP (1) EP1121434B1 (de)
AT (1) ATE408688T1 (de)
CA (1) CA2345379C (de)
DE (1) DE69939593D1 (de)
WO (1) WO2000020578A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121434B1 (de) 1998-10-06 2008-09-17 The University of Queensland Polypeptide zur modulierung des überlebens von zellen
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
AU2002339213A1 (en) * 2001-08-09 2003-02-24 Genset S.A. Migenix agonists and antagonists for use in the treatment of metabolic disorders
AUPS230702A0 (en) * 2002-05-14 2002-06-13 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
AU2003222681B8 (en) * 2002-05-14 2009-06-18 The University Of Queensland A method of treatment
US8637464B2 (en) * 2004-07-14 2014-01-28 Janssen Pharmaceutica N.V. P75NTR screening assay
US20150344535A1 (en) * 2012-09-28 2015-12-03 The University Of Queensland Neurotrophin-tyrosine kinase receptor signaling
US10786543B2 (en) * 2015-09-22 2020-09-29 The Johns Hopkins University P75NTR antagonists and treatment of acute and chronic cardiac disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606023A (en) * 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
EP0846169B1 (de) * 1995-08-04 2003-03-19 Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.D. Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
EP1121434B1 (de) 1998-10-06 2008-09-17 The University of Queensland Polypeptide zur modulierung des überlebens von zellen
AU772811B2 (en) 1998-10-06 2004-05-06 University Of Queensland, The A method of modulating cell survival and reagents useful for same

Also Published As

Publication number Publication date
US20020137188A1 (en) 2002-09-26
EP1121434A1 (de) 2001-08-08
US7919471B2 (en) 2011-04-05
US20110172143A1 (en) 2011-07-14
WO2000020578A1 (en) 2000-04-13
ATE408688T1 (de) 2008-10-15
US20050090442A1 (en) 2005-04-28
EP1121434B1 (de) 2008-09-17
CA2345379C (en) 2011-12-06
EP1121434A4 (de) 2005-03-02
CA2345379A1 (en) 2000-04-13
US8299027B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
DK0888452T3 (da) Human CYR61, et ekstracellulært matrix-signalmolekyle
ATE318905T1 (de) Homologe des tie-rezeptortyrosinekinase liganden
DK1129190T3 (da) Human TSLP DNA og polypeptider
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
NO990086D0 (no) Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
DK0970213T3 (da) Dödsdomæneholdig receptor
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
IL195337A0 (en) Cyr61 compositions and methods
ATE408688T1 (de) Polypeptide zur modulierung des überlebens von zellen
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
ATE391136T1 (de) Fas peptide und antikörper zur modulierung von apoptosis
EP1282722A4 (de) Stabilisierte proteine
ATE259652T1 (de) Neuronale verwendungen des bmp-11
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ATE307826T1 (de) Oligomere von konformationsbeschränkten, nicht- peptidischen di- oder tripeptid-mimetika, und ihre verwendung zur synthese von künstlichen polypeptiden und proteinen
DK0804577T3 (da) cDNA, der koder en BMP type II receptor
CY1105226T1 (el) Dna και πολυπεπτιδια il-1 εψιλον ανθρωπου
EP1187842A4 (de) Der tr10 rezeptor des menschlichen tumor-nekrose-faktors
SE0002364D0 (sv) Growth Factors
WO2003074675A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002077193A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition